Dosage Forms and Strengths: TREMFYA® is available in a 100 mg/mL prefilled syringe and One-Press patient-controlled injector for subcutaneous injection, a 200 mg/2 mL prefilled syringe and ...

Tremfya is the first approved IL-23 inhibitor to offer both IV and fully subcutaneous induction regimens. This approval for Crohn’s disease may make Tremfya a direct competitor with Stelara.

--Johnson& Johnson today announced that the U.S. Food and Drug Administration has approved TREMFYA ® for the treatment of adults with moderately to severely active ulcerative colitis, a chronic ...

Dosage Forms and Strengths: TREMFYA ® is available as 100 mg/mL and 200 mg/2mL for subcutaneous injection and as a 200 mg/20 mL (10 mg/mL) single dose vial for intravenous infusion.

With the results of the three studies, Tremfya has shown its potential to become to the first IL-23 inhibitor to offer two induction options for Crohn’s disease, J&J said in a press release.

Dosage Forms and Strengths: TREMFYA ® is available as 100 mg/mL and 200 mg/2mL for subcutaneous injection and as a 200 mg/20 mL (10 mg/mL) single dose vial for intravenous infusion.

Tremfya is already approved for UC with an IV induction phase followed by injection-based maintenance therapy, securing FDA approval in September.

Johnson & Johnson (NYSE: JNJ) said a Phase 3 study of its drug Tremfya as a subcutaneous induction therapy was shown to be effective in treating adults with moderate-to-severe Crohn’s disease.

New data show TREMFYA® (guselkumab) is the only IL-23 inhibitor proven to significantly inhibit progression of joint structural damage in active psoriatic arthritis ...

The most common side effects of TREMFYA® include: upper respiratory infections, headache, injection site reactions, joint pain (arthralgia), diarrhea, stomach flu (gastroenteritis), fungal skin ...

The FDA has approved Johnson & Johnson’s Tremfya, a dual acting interleukin-23 inhibitor, for the treatment of patients with moderately to severely active ulcerative colitis, according ...

The FDA has approved Tremfya® (guselkumab) for the treatment of adult patients with moderately to severely active ulcerative colitis (UC).